Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Comprehensive” Drug Shortage Mitigation Bill Under Development In House

Executive Summary

Like the Senate proposal, it could include reimbursement rate adjustments in addition to requiring early notification of shortages by manufacturers, but questions remain about ensuring there are no unintended consequences.

You may also be interested in...



Drug Shortage Bill In House Refines Hatch Reimbursement Proposal

Sterile injectable products with three or fewer manufacturers would get better federal reimbursement rates in an effort to attract more producers to the market; H.R. 6611 was modeled after a similar proposal from Sen. Orrin Hatch, R-Utah.

Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives

The Utah Republican’s draft bill would encourage industry to increase its capacity to manufacture sterile injectable drug products by providing higher reimbursement rates and exclusivity incentives. House Republicans continue to pursue economic options, but time and jurisdictional factors could work against such measures to address shortages.

Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives

The Utah Republican’s draft bill would provide higher reimbursement rates for sterile injectable products and provide exclusivity incentives. House Republicans continue to pursue economic options, but time and jurisdictional factors could work against such measures to address shortages.

Related Content

Topics

UsernamePublicRestriction

Register

PS054041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel